Makers of weight-loss drugs, the hottest segment of the pharmaceutical market just now, weren't looking so hot on the stock exchange Tuesday. A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement levels.

The best metric is not weight, but a particularly toxic kind of fat.

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and diabetes drugs Zepbound and Mounjaro off a list of medicines in short supply,

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro soared in the first quarter.